Zealand Pharma, ZP9830, Kv1.3 Ion Channel Blocker, Phase 1 Clinical Trial, Multiple Ascending Dose, Autoimmune Diseases, Inflammatory Diseases, Plaque Psoriasis, Immunology

COPENHAGEN, Denmark, October 19, 2026 Zealand Pharma A/S (NASDAQ: ZEAL), a biotechnology company developing medicines for metabolic health and...